Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enzastaurin Plus R-CHOP Versus R-CHOP in Treatment-Naive Subjects With High-Risk Diffuse Large B-Cell Lymphoma Who Possess the Novel Genomic Biomarker DGM1™

NCT03263026 is registered in ClinicalTrials.gov with Denovo Biopharma LLC as lead sponsor.

NCT NCT03263026
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03263026 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enzastaurin Plus R-CHOP Versus R-CHOP in Treatment-Naive Subjects With High-Risk Diffuse Large B-Cell Lymphoma Who Possess the Novel Genomic Biomarker DGM1™
Lead sponsor
Denovo Biopharma LLC
Phase
Phase 3
Overall status
Completed
Start date
March 20, 2018
Completion date
August 11, 2022
Enrollment
256 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma